Human Pluripotent Stem Cell Biosafety Screening

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for toxicity testing, particularly for teratogenic potential, are labor-intensive, costly, and less accurate due to disparities between animal models and human responses, necessitating the development of more efficient and relevant in vitro models.

Innovation Solution

The use of differentiating human pluripotent stem cells, such as embryonic stem cells and induced-pluripotent stem cells, to analyze gene expression changes in response to agents, with specific criteria for determining biosafety based on the number of differentially expressed genes, particularly tissue-specific and fetal development-associated genes.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If in vivo animal models are used for teratogenicity testing, then the testing can be performed with established protocols, but the results show significant disparities between animal responses and human responses

Engineering Contradiction:

Improveaccuracy of teratogenicity predictionVSAvoidrelevance to human response

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent uses human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs) as an in vitro model that copies human embryonic development processes. This cellular model system replicates human-specific biological responses to teratogens, eliminating the species disparity problem inherent in animal models while maintaining the ability to conduct systematic toxicity screening

Inventive Principle:

Principle #26Copying

Solution Approach 2:

The patent changes the fundamental parameter of the testing system from cross-species animal models to human-specific cellular models. By using hESCs and hiPSCs that differentiate into human embryonic tissues, the system transforms the biological basis of testing to match human physiology, thereby improving predictive accuracy for human teratogenicity

Inventive Principle:

Principle #35Parameter changes

2Reliability

If traditional in vivo toxicity testing is conducted following OECD guidelines, then comprehensive safety data can be obtained, but the process requires large numbers of animals and is very labor intensive and costly

Engineering Contradiction:

Improvecompleteness of safety assessmentVSAvoidefficiency of testing process

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent replaces the mechanical and logistical complexity of in vivo animal testing with an in vitro cellular assay system. By substituting living animals with cultured human stem cells, the system eliminates housing, care, and ethical requirements while maintaining safety assessment capabilities through gene expression analysis and cellular phenotype evaluation

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent segments the complex in vivo teratogenicity testing process into discrete in vitro assays using differentiated human stem cell lines. Instead of requiring entire animal models, the system divides the testing into specific cellular and molecular readouts that can be performed independently, increasing throughput and reducing resource requirements

Inventive Principle:

Principle #1Segmentation

3Reliability

If safe margins are calculated from animal NOAEL values, then regulatory requirements can be met, but it is difficult to separate actual teratogenic effects from non-specific maternal toxicity effects

Engineering Contradiction:

Improveaccuracy of safety margin determinationVSAvoidcomplexity of effect differentiation

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies local quality by using specifically differentiated human stem cell lineages (ectoderm, mesoderm, endoderm) that are sensitive to particular teratogenic mechanisms. Each differentiated cell type provides localized information about specific tissue vulnerability, allowing differentiation between direct teratogenic effects on embryonic tissues versus indirect maternal toxicity effects

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach allows for a more efficient and accurate assessment of teratogenic potential by reducing the need for animal testing and providing a human-relevant model, enabling safer identification of toxic agents through gene expression analysis.

Implementation Method 1

analyzing a level of gene expression of a plurality of genes in the differentiating human pluripotent stem cells

Methodology Applied

Scientific EffectGene expression analysis:

Data Source

PatentUS8945847B2Methods and kits for ascertaining biosafety of an agent

Publication Date: 2015.02.03 YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD

AI summary

A method of ascertaining the bio-safety of an agent is disclosed. The method comprises:(a) contacting the agent with differentiating human pluripotent stem cells;(b) analyzing a level of gene expression of a plurality of genes in the differentiating human pluripotent stem cells, wherein the agent is qualified as being safe if at least one of the following qualification parameters are fulfilled:(i) the agent causes a difference in the level of gene expression below a predetermined number of genes as compared to control differentiating human pluripotent stem cells that have not been contacted with the agent;(ii) the agent causes a difference in gene expression below a predetermined number of tissue-specific genes of a tissue as compared to control differentiating human pluripotent stem cells that have not been contacted with the agent; or(iii) the agent causes a difference in gene expression below a predetermined number of genes involved in fetal development as compared to control differentiating human pluripotent stem cells that have not been contacted with the agent.